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Abstract:   Cervix cancer is an HPV (Human papillomavirus) related cancer, and HPV positivity 
is necessary even if there is no cytology abnormality. We aimed to determine the ratios of 13 
high-risk HPV types in cases with high-risk HPV positivity without cervical smear pathology re-
ferred to our clinic and to determine the relation of HPV types with age, parity, menopausal sta-
tus, and abnormal histopathological results. Two hundred forty-one cases included in the study, 
which referred to us because of HPV positivity and colposcopically biopsied between January 
2014 to January 2018. HPV prevalences were investigated. The relationship between HPV 
types and variables such as age, parity, menopausal status examined. The mean age of 241 
patients included in the study was 46,1+8,8. The parity average was 2,4+1,1. Sixty-five of the 
patients (27%) were postmenopausal. Of the 241 HPV-positive patients, 172 (71,4%) had only 
high-risk HPV viruses. The frequency ranking of HPV types was as follow; 16, 31, 51, 56, 18, 
52, 35, 58, 39, 68, 45, 33 and 59. According to the HPV types, the average ages were as fol-
low; 18 (43,6 years), 33 (40,1 years) and 51 (41,9 years) were younger than the average age. 
35 (48,7 years), 39 (48,5 years), 52 (49,1 years) and 68 (51,3 years) were older than the aver-
age age. 16 (44,9 years), 31 (47,9 years), 45 (44,3 years), 56 (47,3 years), 58 (46,9 years) and 
59 (46,7 years) was similar the average age. There was no significant difference between the 
parities according to HPV types (2 to 2,7). According to the HPV types, the menopausal state 
was as follows; 39 (50%), 56 (50%) and 68 (53,8%) mostly observed in the postmenopausal 
period; A small proportion of 33 cases (12,5%) was postmenopausal. The rate of severe dys-
plasia according to colposcopic biopsy related with HPV types was; 58 (40%), 56 (30,8%), 18 
(28%), 45 (27,3%), 31 (26,1%), 39 (25%), 59 (16,7%), 35 (14,3%), 51 (13,8%), 33 (12,5%), 16 
(11,8%), 52 (8,3%). The prevalence of HPV types, the age at which they saw, the menopausal 
status and the potential for the formation of severe dysplasia are highly variable. We think that 
routine screening programme, colposcopy indications and vaccination program should cover all 
HPV types according to data.   
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INTRODUCTION 
Various infectious agents, especially 
Hepatitis B (HBV), Hepatitis C (HCV), Human 
papillomavirus (HPV) and Helicobacter pylori, 
account for 23% of the causes of human can-
cer (WHO Global Cancer Report, 2003). 
Among HPV infectious agents, it is essential 
because of the most frequent association with 
cancer and the most common sexually trans-
mitted disease (Depuydt et al., 2016; Chattzis-
tamatiou et al., 2016; Kim, 2017). HPV is a 
small double-stranded DNA virus that has 
been described more than 200 types daily. 
This difference provides the genetic sequence 
of the outer capsid protein L1. It has been 
found that about 40 of this family of viruses go 
through sexual contact and cause infection in 
the basal epithelium layer of the genital muco-
sa in both men and women (CDC HPV report, 
2015; Sah et al., 2018). HPV infections heal 
spontaneously within 1 to 2 years in 70-90% 
(Cubie, 2013). Persists are known to cause 
vulvovaginal, penile, anal, head and neck can-
cers, especially cervical cancer with oncogenic 
effect (Depuydt et al., 2016; ICO/IARC HPV 
and Related Diseases Report, 2017). 
HPV viruses are divided into two groups 
as low risk (LR HPV) and high (HR HPV) risk 
compared to cancer development potentials.  
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International cancer research agency (IARC) 
recently identified 25 HR HPV in 2012. These 
are in turn; 16, 18, 26, 30, 31, 33, 34, 35, 39, 
45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 
73, dir (Humans Biological agents, 2012). 
Cervical cancer among HPV-related dis-
eases is the fourth most common cancer seen 
in women worldwide — the second most com-
mon cancer in women aged 15 to 44 years. 
Every year more than 500,000 women are di-
agnosed, and approximately 265,000 women 
die from this cancer (ICO/IARC HPV and Re-
lated Diseases Report, 2017). 
 When we work on this information, we 
try to show the frequency of HPV types in our 
region. We also investigated the relationship 
between HPV types and age, menopausal sta-
tus, and abnormal histopathology results.  
 
MATERIALS AND METHODS 
 Ordu Provincial Health Directorate and 
Ordu University Medical Faculty Training and 
Research Hospital Clinical Practice Ethics 
Committee approvals obtained (Date: 
26/04/2018, Number: 2018-73). My study in-
cluded 241 patients between January 2014 
and January 2018 who underwent colposcopic 
biopsy with a normal cytology referred to ours 
due to HPV positivity. Patients with HPV and 
cytologic examinations made by the Center for 
Cancer Early Diagnosis Screening and Train-
ing (KETEM), a national screening organiza-
tion. In this organization women aged between 
30 and 65 years are invited for HPV based 
screening by family physicians every five 
years. Two samples are taken from each wom-
an to enable cytology testing in those found to 
be HPV positive without the need for a sepa-
rate visit. The first sample is collected with a 
brush and transferred to a glass slide for con-
ventional cytology. The second is taken with a 
different brush and put into 5 ml of Standard 
Transport Medium for HPV DNA analysis. And 
the result report is sent to the medical profes-
sional to be shared with the patient. The col-
poscopy examination and biopsy results of the 
patients were retrospectively scanned and re-
trieved from the hospital registry system 
The 13 high oncogenic HPV types ex-
amined by KETEM were as follows; 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, 68. For 
women who are HPV positive by Hybrid Cap-
ture2 (Qiagen), genotyping performed with the 
CLART kit (Genomics). HPV results were ana-
lyzed, and the prevalences of HPV types sub-
tracted. The relationship between variables 
such as age, parity, menopausal status and 
HPV types was examined. 
In progressing cervical cancer, cervical 
preinvasive lesions are significant. According 
to the classic classification of cervical preinva-
sive lesions; colposcopic biopsy results classi-
fied as Normal, CIN I, CIN II, CIN III, and CIS 
(cervical carcinoma in situ). CIN II and ad-
vanced cases (which have high risk potential 
for cervical cancer) were evaluated as severe 
dysplasia. The rates of severe dysplasia of 
HPV types investigated. 
 All data analyses were done by SPSS 
20.0. One Way ANOVA and T-Test were used 
due to group number to analyze data consist 
with independent measurements showing nor-
mal distribution. Pearson Correlation Test was 
used to determine the relation¬ship between 
the groups. To analyze the variations that do 
not distribute normally, Kruskal Wallis and 
Mann-Whitney U tests used. Spearman Corre-
lation Test was used to determine relationship 
between the groups. Data in a categorical 
structure analyzed by Chi square test. A p-
value <0.05 was accepted as significant.  
 
RESULTS AND DISCUSSION 
 The mean age of 241 patients included 
in the study was 46.1 + 8.8. The parity average 
was 2.4 + 1.1. Sixty-five of the patients (27%) 
were postmenopausal. Of the 241 HPV-
positive patients, 172 (71.4%) had single, 48 
(19.9%) had two, 15 (6.2%) had three, 5 
(2.1%) had four, 1 (0.4%) had five high-risk 
HPV viruses were detected. (Table 1 and 2). 
 
The mean age 46.1 + 8.8 
The parity average 2.4 + 1.1 
The postmenopausal ratio 27% (65/241) 
Table 1. The General Information 
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Table 2. High-risk HPV Distribution  
One high-risk HPV 172 patients 71.4% 
Two high-risk HPV 48 patients 19.9% 
Three high-risk HPV 15 patients 6.2% 
Four high-risk HPV 5 patients 2.1% 
Five  high-risk HPV 1 patient 0.4% 
Table 3. The frequency ranking and the mean ages of HPV types (According to the incidence) 
16 93 44.9 
31 46 47.9 
51 29 41.9 (younger) 
56 26 47.3 
18 25 43.6 
52 24 49.1 (older) 
35 21 48.7 
58 20 46.9 
39 16 48.5 
68 13 51.3 (older) 
45 11 44.3 
33 8 40.1 (younger) 
59 6 46.7 
Table 4. The rate of detection of severe dysplasia after colposcopic biopsy 
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 The frequency ranking of HPV types 
was as follows; 16 (93 patients), 31 (46 pa-
tients), 51 (29 patients), 56 (26 patients), 18 
(25 patients), 52 (24 patients), 35 (21 pa-
tients), 58 (20 patients), 39 (16 patients), 68 
(13 patients), 45 (11 patients), 33 (8 patients), 
and 59 patients (6 patients).  
 According to the HPV types, the mean 
age was as follows; 33 (40.1) and 51 (41.9) 
were younger than the average age. 52 (49,1) 
and 68 (51,3) were older than the average 
age. 16 (44.9), 18 (43.6),  31 (47.9), 35 (48,7), 
39 (48,5), 45 (44.3), 56 (47.3), 58 (46.9) and 
59 (46.7)  was observed like the average age. 
(Table 3). There was no significant difference 
between the parties according to HPV types (2 
to 2.7). (p>0.05).  
According to the HPV types, the meno-
pausal state was as follows. 39 (50%), 56 
(50%) and 68 (53.8%) were observed in the 
postmenopausal period; A small proportion of 
33 cases (12.5%) were postmenopausal. 
 The rate of detection of severe dyspla-
sia after colposcopic biopsy was 67/241 
(27,8%). The rates of severe dysplasia accord-
ing to HPV types were as follows; 58 (40%), 
56 (30.8%), 18 (28%), 45 (27.3%), 31 (26.1%), 
39 (25%), 68 (23.1), 59 (16,7%), 35 (14,3%), 
51 (13,8%), 33 (12,5%), 16 (11,8%), 52 
(8,3%). (Table 4).  
The HPV DNA testing now has shown 
as the primary screening program by many or-
ganizations, notably the World Health Organi-
zation (WHO) and the International Agency for 
Research on Cancer (IARC). In cervical can-
cer screening, many high-income countries 
such as Norway, the Netherlands and Austral-
ia now use HPV DNA testing in cancer screen-
ing programs instead of conventional cervical 
smear screening (Anttila et al.,2015; Huh et 
al., 2015). Turkey cervical cancer screening 
program based on data from the population 
screening HPV DNA test screening 5 - 6 points 
increase reported to provided. It has also been 
shown that this program has additional ad-
vantages, such as less human workload, faster 
results, less need for sampling, and fewer hos-
pital visits (Gultekin et al., 2018). 
The prevalence of HPV in the world is 
highly variable compared to geographical re-
gions. The HPV frequency in the community is 
around 10% (1.4% - 25.6%). Also, 95% to 
100% of patients with cervical cancer have a 
close relationship with the virus and cancer 
(Walboomers et al., 1999; Basu et al., 2011; 
Kirschner et al., 2013). 
In Turkey, there are many studies 
demonstrating the HPV prevalence (2% - 
25%). In a retrospective analysis of 6388 pa-
tients who referred to member centers for the 
Turkish gynecologic oncology group, the HPV 
positivity rate was 25%. The high prevalence 
in this study can be attributed to the fact that 
the centers participating in the study are refer-
ee oncologic centers (Dursun et al., 2013). 30 
- a million women are screened from age 65 
for Turkey, according to the results of cervical 
cancer screening and HPV positivity in our 
country was 3.5% (Walboomers et al., 1999). 
 On the other hand, common HPV types 
also vary from region to region. The 5 most 
common types of HPV were 16, 53, 52, 18, 39; 
In Europe 16, 18, 31, 33, 58; In Asia there are 
16, 52, 58, 18, 56 (Barut et. al., 2018). Turkey 
study also showed that Turkey's peculiar distri-
bution; 16 (20,7%), 51 (10,8%), 31 (8,7%), 52 
(7,1%), 56 (5,7%). For example, the uncom-
mon type observed in other regions 51 to the 
second common in Turkey. Such as having a 
high oncogenic Type 16 18 Turkey ranks sev-
enth in the study. Also common in North Amer-
ica, Asia and type 52 and type 31, which is still 
in the top five in Europe is often seen in Tur-
key shows that we are a mosaic of countries 
regarding HPV (Walboomers et al., 1999). 
In our study, the first five HPV types 
were as follows; 16 (38,5%), 31 (19,1%), 51 
(12%), 56 (10,8%) and 18 (10,4%). We found 
some differences sailed close to Turkey as 
well as the general data of our study data. 
Prevalence of Turkey was 12.6% higher than 
other studies because the data in Turkey (13 
HR HPV types external olds) HPVs not di-
rected by us. In addition, depending on the 
type of high referral rates by 16 family physi-
cians and 18 types, we found extremely high 
data rates compared to Turkey. We also had 
our differences in the method of operation with 
Turkey. Turkey abnormal cytology 19.1% of 
HPV-positive patients in the studies of HPV 
positivity we left off work to show the inde-
pendent effects of abnormal cytology. Finally, 
we found that type 31 was higher than type 51 
when we were working on a possible regional 
difference. 
In our study, we found that HPV 16 and 
18 positivity observed in 46.9% of patients.  
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However, we believe that 16 and 18 non-HR 
HPV ratios are quite high, and 16 and 18 of 
the potential for severe dysplasia considered. 
The incidence of single / multiple HPV preva-
lence, such as HPV prevalence, was also 
found at quite different rates in studies. In a 
large-scale Chinese study, 79% of the cases 
had a uniform infection rate, while a recent 
study from our country yielded multiple infec-
tion rates of 59% (Barut et al., 2018; Tao et al., 
2018). In our study, the odd infection rate was 
more than 71.4%. 
 According to HPV types, 18, 33, 51 ob-
served at younger ages than mean age; 35, 
39, 52, 68 were older than the average age. 
On the other hand, there was no significant 
difference between the parities according to 
HPV types (2 to 2.7). Also, more than half of 
39, 56 and 68 cases observed in the postmen-
opausal period; A relatively small proportion of 
33 cases (12.5%) were postmenopausal. 
The HPV test scans the conventional 
smear. One million women screened by Tur-
key in 3499 women working colposcopy di-
rected in 1869 (53.4%) observed in any cervi-
cal smear abnormalities. However, colposcop-
ic biopsy results showed 708 CIN I (20,2%), 
285 CIN II (8,1%), 436 CIN III (12,4%) and 85 
cancer (2,4%). The most important outcome of 
the study was the ability to skip 45.9% of CIN 
III and advanced cases with conventional 
smear scanning (Walboomers et al., 1999). 
The incidence of severe dysplasia in Turkey 
operating in the HPV positivity in our study, 
while 22.9% of patients with pathology cervical 
smear to exclude Although we rate rose to 
27.8%. 
 In our study, we also performed a re-
view of the species. The rate of severe dyspla-
sia after colposcopic biopsy was according to 
HPV types. 58 (40%), 56 (30.8%), 18 (28%), 
45 (27.3%), 31 (26.1%), 39 (25% 59 (16,7%), 
35 (14,3%), 51 (13,8%), 33 (12,5%), 16 
(11,8%), 52 (8,3%). Although we observed 
very little severe dysplasia in Type 16 positivi-
ty, we think it is very important because of the 
most common type of HPV. 
It is known that HPV screening, as well 
as studies on HPV vaccines, are continuing 
rapidly. HPV 16 and 18 were shown to be re-
sponsible for 70% of cervical cancer. And it is 
said that HPV 31, 33, 45, 52 and 58 are an ad-
ditional 22% of cancer cases. And in our study 
we showed that HPV 58, 45 (due to the high 
tendency to dysplasia) and 31, 51, 56 (due to 
frequent occurrence) deserves more attention; 
like HPV 16 and 18. Vaccine studies are car-
ried out in this framework. Cervarix® (16,18) 
and Gardasil® (6,11,16,18) are the first vac-
cines and protect against only 46.9% of HPV 
types in our cases. Finally, Gardasil 9® 
(6,11,16,18,31,33,45,52,58) has been applied 
to the market and is protective against 84.6% 
of the HPV types in our study.  
 We think that vaccine programs should 
develop rapidly and produce new generations 
of vaccines containing only the most common 
types in European countries - inclusive low 
and middle-income countries where deaths 
from the entire world - more often cervical can-
cer deaths - are more common. 
 
CONCLUSION 
 Although reflex cytology suggested in 
the literature with HPV 16-18 non-HR HPV 
positivity, we advocate the necessity of direct 
colposcopy from these cytologic follow-ups. 
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